



February 21, 2008

## **Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets**

SAN CARLOS, Calif., Feb 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year ended December 31, 2007 on Wednesday, February 27, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call for analysts and investors beginning at 5:00 p.m. Eastern Time (ET).

Investors can access the press release and a live audio-only Webcast of the conference call through a link that is posted on the Investor Relations section of the Nektar website: <http://www.nektar.com>. The web broadcast of the conference call will be available for replay through Wednesday, March 12, 2008.

To access the conference call, follow these instructions:

Dial: (866) 314-5232 (U.S.); (617) 213-8052 (international)

Passcode: 94561493 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, March 12, 2008 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 92959414.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled ten approved products for partners, which include the leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

SOURCE Nektar Therapeutics

<http://www.nektar.com/>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX